Fig. 4

Scanning ultrasound (SUS) increases the levels of the Aducanumab analog in the brain. a Fluorescently labeled Adu is detectable in the whole brain (scale bars 1 mm) and when visualized at higher magnification in the cortex and hippocampus (scale bars 100 μm). In APP23 mice treated with Adu alone, the fluorescent Adu is bound to plaques, which were immunolabeled with 4G8 antibody. b The levels of Adu were higher when Adu was delivered together with SUS in SUS + Adu-treated mice. The amyloid plaques in SUS + Adu-treated mice were decorated all over with Adu, whereas in mice treated with Adu alone the Adu is mainly confined to the outsides of the plaques. Microglia as identified by IBA1 immunostaining were located near plaques which have Adu bound to them. c The levels of fluorescent antibody in the cortical brain lysate was greatly increased in the SUS + Adu group compared to the Adu group. Data are represented as mean ± SEM. Statistical differences: *p < 0.05. Data were analyzed with t test. Adu N = 9, SUS + Adu N = 9